FineHeart S.A, a medical device company developing innovative devices for cardiology announced today that it has received authorization from the SUKL (the Czech Republic State Institute for the Control of Medicinal Products) to carry out “A prospective, single arm, single center, First in Human Study to evaluate the safety and performance at 30 days of the FineHeart FLOWMAKER® in subjects with advanced heart failure.”
This first trial will be carried out at the IKEM in Prague (The Institute for Clinical and Experimental Medicine), one of Europe’s leading centers of excellence for cardiac research, heart transplants, and LVAD implantation (Left Ventricular Assist Device).
“This authorization marks a major milestone in the development of FineHeart. It results from many years of hard work by our teams and partners, as well as our investors’ loyal and unrelenting support. Reaching this point reflects our unwavering commitment to push forward the boundaries of medical device technology to bring hope to patients suffering from severe heart failure. This new treatment is designed to help patients regain their independence and improve their quality of life.”declared Arnaud Mascarell, CEO & co-founder of FineHeart.
“We are delighted to start our clinical program with the team of Professor Ivan Netuka, Chair of the Cardiovascular Surgery Department at IKEM. He will serve as the trial’s principal investigator. Thanks to his department’s unique expertise in international innovative clinical studies and conventional LVAD therapy, the medical team will be able to demonstrate the ease and short implantation procedure of the FLOWMAKER® in a beating heart. Given the device’s unique features it aims to significantly reduce the complications observed with LVADs.” said cardiologist Dr. Stephane Garrigue, theinventor of the FLOWMAKER®and CSO of FineHeart.
About The FLOWMAKER®
The FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart’s natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device – barely 10 cm in size – that is adjustable to patients’ needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.
Second cause of death in the world after cancer, severe heart failure is a degenerative disease that progresses to a severe form, resulting in an inability of the heart to contract effectively. Each year, 200,000 patients are not managed effectively due to lack of treatment.
Source link : https://www.businesswire.com/
